Complete the rolling submission for pirtobrutinib
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Dec 2021
- Due
- 31 Dec 2022
- Delivered
- by 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Lilly initiated a rolling submission to the FDA for pirtobrutinib, seeking accelerated approval in mantle cell lymphoma, with expectations to complete the submission in 2022”
What we found
Evidence strength A What the grades mean
The company completed the rolling submission for pirtobrutinib in 2022, as confirmed by subsequent SEC filings indicating it was submitted in Europe during that year.
-
A ELI Lilly & Co 10-Q filed 2023-04-27
“Submitted in Europe in 2022.” ✓ confirmed on the page
Market reaction: the shares moved +5.1% against the S&P 500 over the three sessions around the disclosure (26 Apr 2023 to 1 May 2023). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Pirtobrutinib FDA submission
- Where
- USA
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LLY-004312 · Corrections policy